← Back to Search

Monoclonal Antibodies

Olaratumab for Soft Tissue Sarcoma

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to death from any cause (approximately 30 months)
Awards & highlights

Study Summary

This trial is testing a new combination cancer treatment to see if it is safe for people who have previously been treated for advanced or metastatic soft tissue sarcoma.

Eligible Conditions
  • Soft Tissue Sarcoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to death from any cause (approximately 30 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to death from any cause (approximately 30 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with Olaratumab Dose Limiting Toxicities (DLTs)
Secondary outcome measures
Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and Stable Disease (SD)
Duration of response (DoR)
Number of Participants with Anti-Olaratumab Antibodies When Administered in Combination with Pembrolizumab
+6 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Olaratumab Dose Level 2 + PembrolizumabExperimental Treatment2 Interventions
Olaratumab given IV and pembrolizumab given IV.
Group II: Olaratumab Dose Level 1 + PembrolizumabExperimental Treatment2 Interventions
Olaratumab given intravenously (IV) and pembrolizumab given IV.
Group III: Olaratumab + Pembrolizumab ExpansionExperimental Treatment2 Interventions
Olaratumab given IV and pembrolizumab given IV.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Olaratumab
2010
Completed Phase 2
~1300
Pembrolizumab
2017
Completed Phase 2
~1950

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,603 Previous Clinical Trials
3,199,592 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,860 Previous Clinical Trials
5,047,816 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,336 Previous Clinical Trials
403,767 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What maladies is Olaratumab typically employed to address?

"Olaratumab is often utilized to treat malignant neoplasms, while it has also been known to provide relief for sufferers of unresectable melanoma, microsatellite instability high, and chemotherapy-induced disease progression."

Answered by AI

What adverse effects have been observed in patients taking Olaratumab?

"Data regarding Olaratumab's efficacy and safety is scarce, which has led to our team at Power giving it a score of 1."

Answered by AI

What is the current enrollment capacity of this research endeavor?

"At this moment, no further recruitment is needed for the study which was initially listed on 3rd July 2017 and lastly updated 19th July 2022. If you are looking to join other studies, there are currently 444 trials with an open enrollment policy for sarcoma and 962 clinical trial spots available for Olaratumab."

Answered by AI

Are there any opportunities to enroll in this trial at the present time?

"According to the clinicaltrials.gov database, this trial is no longer recruiting subjects; it was last updated on July 19th 2022 after initially being posted on March 7th 2017. Nevertheless, there are currently 1,406 other studies actively looking for volunteers."

Answered by AI

What additional investigations have been conducted using Olaratumab?

"Currently, there are 962 distinct clinical studies being conducted into Olaratumab. 123 of these trials have reached Phase 3 and 35861 medical centres globally are running the experiments. Houston, Texas is a major hub for research into this drug."

Answered by AI
~5 spots leftby Mar 2025